CN116322785A - 包含il-10的双细胞因子融合蛋白 - Google Patents

包含il-10的双细胞因子融合蛋白 Download PDF

Info

Publication number
CN116322785A
CN116322785A CN202080105253.9A CN202080105253A CN116322785A CN 116322785 A CN116322785 A CN 116322785A CN 202080105253 A CN202080105253 A CN 202080105253A CN 116322785 A CN116322785 A CN 116322785A
Authority
CN
China
Prior art keywords
leu
gly
ser
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080105253.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·穆姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deka Biosciences
Original Assignee
Deka Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deka Biosciences filed Critical Deka Biosciences
Publication of CN116322785A publication Critical patent/CN116322785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080105253.9A 2020-07-20 2020-12-02 包含il-10的双细胞因子融合蛋白 Pending CN116322785A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054208P 2020-07-20 2020-07-20
US63/054,208 2020-07-20
PCT/US2020/062907 WO2022019945A1 (en) 2020-07-20 2020-12-02 Dual cytokine fusion proteins comprising il-10

Publications (1)

Publication Number Publication Date
CN116322785A true CN116322785A (zh) 2023-06-23

Family

ID=79291996

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080105253.9A Pending CN116322785A (zh) 2020-07-20 2020-12-02 包含il-10的双细胞因子融合蛋白

Country Status (11)

Country Link
US (19) US11292822B2 (https=)
EP (1) EP4181957A4 (https=)
JP (1) JP2023534847A (https=)
KR (1) KR20230096959A (https=)
CN (1) CN116322785A (https=)
AU (1) AU2020459746A1 (https=)
BR (1) BR112023001187A2 (https=)
CA (1) CA3186753A1 (https=)
IL (1) IL300062A (https=)
MX (1) MX2023000948A (https=)
WO (1) WO2022019945A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
CN118900697A (zh) * 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法
KR20250078792A (ko) * 2023-11-24 2025-06-04 주식회사 메드팩토 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞，其制备方法及抗纤维化的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
CN106349393A (zh) * 2015-12-21 2017-01-25 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
EA200802289A1 (ru) 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
WO2009056268A1 (en) 2007-10-30 2009-05-07 Philogen S.P.A. An antigen associated with rheumatoid arthritis
NZ592420A (en) 2008-10-02 2012-12-21 Emergent Product Dev Seattle Cd86 antagonist multi-target binding proteins
US9249225B2 (en) * 2010-05-26 2016-02-02 Regents Of The University Of Minnesota Single chain variable fragment anti-CD133 antibodies and uses thereof
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
KR102277469B1 (ko) 2011-12-12 2021-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
CN104245722A (zh) 2012-02-29 2014-12-24 Ambrx公司 白细胞介素-10多肽结合物和其用途
CA2876285A1 (en) * 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
RU2612878C2 (ru) * 2012-10-03 2017-03-13 Филоджен С.П.А. Антигены, ассоциированные с воспалительным заболеванием кишечника
KR20160043927A (ko) 2013-03-14 2016-04-22 파카쉬 길 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR101811050B1 (ko) 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2017091611A1 (en) 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
CA3044556C (en) 2016-04-12 2020-11-17 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018156791A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
EP3625253A4 (en) * 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
JP2022524018A (ja) 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
US20210214782A1 (en) 2020-01-09 2021-07-15 Deka Biosciences, Inc. Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment
AU2021257439A1 (en) 2020-04-13 2022-12-15 University Health Network Methods for treating cytokine release syndrome
CA3186753A1 (en) * 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
CA3215528A1 (en) 2021-05-11 2022-11-17 Salvatore Albani Chimeric antigen receptors and modified cells comprising the same
JP2024546938A (ja) 2021-12-13 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質
JP2024546999A (ja) 2021-12-16 2024-12-26 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー
CN118900697A (zh) 2022-02-22 2024-11-05 德卡生物科学公司 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
CN106349393A (zh) * 2015-12-21 2017-01-25 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. STEEN-LOUWS等: "IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10", 《CLINICAL AND EXPERIMENTAL IMMUNOLOGY》, vol. 9, no. 1, 31 January 2019 (2019-01-31), pages 1 - 9, XP055648632, DOI: 10.1111/cei.13224 *
CORNELIA HUTMACHER等: "Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy", 《ADVANCED DRUG DELIVERY REVIEWS》, vol. 15, no. 141, 7 September 2018 (2018-09-07), pages 67 - 91, XP085750642, DOI: 10.1016/j.addr.2018.09.002 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025148750A1 (zh) * 2024-01-08 2025-07-17 上药生物治疗（香港）有限公司 膜表达il-10及其用途

Also Published As

Publication number Publication date
US11608368B2 (en) 2023-03-21
US12110317B2 (en) 2024-10-08
US11618775B2 (en) 2023-04-04
US20240067688A1 (en) 2024-02-29
US11629178B2 (en) 2023-04-18
US20220275040A1 (en) 2022-09-01
US12116393B2 (en) 2024-10-15
AU2020459746A1 (en) 2023-03-16
US12116391B2 (en) 2024-10-15
BR112023001187A2 (pt) 2023-04-04
CA3186753A1 (en) 2022-01-27
US20220281935A1 (en) 2022-09-08
US12263358B2 (en) 2025-04-01
US20220267397A1 (en) 2022-08-25
US20240059748A1 (en) 2024-02-22
MX2023000948A (es) 2023-04-14
US20250135241A1 (en) 2025-05-01
US20240076337A1 (en) 2024-03-07
US12268903B2 (en) 2025-04-08
US20220340631A1 (en) 2022-10-27
US20220017587A1 (en) 2022-01-20
IL300062A (en) 2023-03-01
US12116390B2 (en) 2024-10-15
US11572397B2 (en) 2023-02-07
WO2022019945A1 (en) 2022-01-27
US20240059749A1 (en) 2024-02-22
US11613563B2 (en) 2023-03-28
US20240076339A1 (en) 2024-03-07
US20240059750A1 (en) 2024-02-22
US12121755B2 (en) 2024-10-22
US12116392B2 (en) 2024-10-15
US20220380428A1 (en) 2022-12-01
US20220275039A1 (en) 2022-09-01
US12145007B2 (en) 2024-11-19
US20240076335A1 (en) 2024-03-07
JP2023534847A (ja) 2023-08-14
US11292822B2 (en) 2022-04-05
US20220380427A1 (en) 2022-12-01
US20240067687A1 (en) 2024-02-29
US20240076336A1 (en) 2024-03-07
US12006346B2 (en) 2024-06-11
KR20230096959A (ko) 2023-06-30
US12116389B2 (en) 2024-10-15
US20240076338A1 (en) 2024-03-07
EP4181957A4 (en) 2024-08-07
EP4181957A1 (en) 2023-05-24
US12122814B2 (en) 2024-10-22

Similar Documents

Publication Publication Date Title
US12006361B2 (en) Albumin binding domain fusion proteins
CN116322785A (zh) 包含il-10的双细胞因子融合蛋白
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
EP3013859B1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
KR20210139312A (ko) Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
CA2656700A1 (en) Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
CN118451096A (zh) 异二聚体fc细胞因子及其用途
KR20240067113A (ko) Il-21r 뮤테인을 포함하는 면역 사이토카인
JP7404343B2 (ja) 融合タンパク質、並びに腫瘍及び／又はウイルス感染の治療薬を製造するためのその使用
CN112409484A (zh) 多功能抗体、其制备及其用途
CN114053403A (zh) 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
CN114616247B (zh) Ox40/pd-l1双特异性抗体
RU2836849C2 (ru) Вариантные молекулы il-10 и способ лечения злокачественной опухоли
RU2858560C2 (ru) Молекулы, связывающие gp130, и способы их применения
US20250236653A1 (en) Targeted low potency il-12 fc fusion proteins and uses thereof
US20230279092A1 (en) Immunocytokines for treatment of autoimmune and inflammatory conditions
HK40126456A (en) Albumin binding domain fusion proteins
RU2786444C2 (ru) Слитые белки с альбумин-связывающими доменами
WO2025221933A9 (en) Antibodies and polypeptides comprising variant fc regions
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
CA3260711A1 (en) Fusion protein
HK40114315A (zh) 包含抗cd73抗体和il-2的融合蛋白及其用途
CN119487194A (zh) 融合蛋白
HK40066344B (zh) Ox40/pd-l1双特异性抗体
HK40066344A (zh) Ox40/pd-l1双特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination